Halozyme Therapeutics Inc

Halozyme Therapeutics Inc Stock

23.76P/E
€9.66BMarket capitalisation
US$4.00Earnings
—Dividend yield

Current price

—
1D
1W
1M
3M
6M
1Y
3Y
Max

Company description

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Halozyme Therapeutics Inc is registered in the following country: United States of America (Exchange: USNASD).

Key metrics

Key metrics and master data for the Halozyme Therapeutics Inc stock.

Market capitalisation
€9.66B
P/E
23.76
P/B
35.68
P/S
6.45
P/CF
11.99
Issued shares 114M Units

Return

Here you can see the performance of the Halozyme Therapeutics Inc stock.

PeriodPerfor­mance
1 Week-7.82 %
1 Month-22.78 %
3 Months-7.40 %
6 Months-3.63 %
1 Year+18.31 %
YTD-2.51 %

Dividends

With an (expected) annual dividend of —, the current stock price results in a dividend yield of —.

Dividend type—
(Expected) annual dividend —
Dividend yield —

Splits

The table shows the splits of the Halozyme Therapeutics Inc share.

DateRatio
No data available.

Which ETF contains the Halozyme Therapeutics Inc stock?

The Halozyme Therapeutics Inc stock is contained in a total of 0 ETFs with at least 1%. You can find a list of these ETFs in the following table. With —, Halozyme Therapeutics Inc has the largest weight in .

Name
Weighting
Region
Country
TER
Replication
Volume (£m)

Frequently asked questions

Here you can find all answers to your questions about the Halozyme Therapeutics Inc stock.

Master data is provided by Morningstar (stocks, ETFs, funds), CoinGecko (cryptocurrencies) and Isarvest GmbH. Price data is at least 15-minute delayed exchange prices (stocks, ETFs, funds) or NAV prices (ETFs, funds). Real-time prices – where available – are provided by the providers and Lang & Schwarz (stocks, ETFs, funds) and CoinGecko (cryptocurrencies).

Isarvest GmbH assumes no liability for the information presented and cannot guarantee that the data is complete and accurate.

Affiliate notice *
Links marked with an asterisk (*) are advertising or affiliate links. If you purchase or sign up through this link, we receive compensation from the provider. This comes at no additional cost or disadvantage to you. We use this revenue to fund our free services. Thank you for your support.